In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.
The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in late 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA).
IGBA is committed to promoting generic and biosimilar medicines by exchanging information worldwide through constant dialogue with the ICH, WHO, WTO, WIPO and other international organization.
IGBA consists of the following associations:
- Association for Accessible Medicines (AAM-USA)
- Canadian Generic Pharmaceutical Association (CGPA-Canada)
- Generic & Biosimilar Medicines Southern Africa (GBM-Southern Africa)
- Japan Generic Medicines Association (JGA-Japan)
- Jordanian Association of Pharmaceutical Manufacturers (JAPM-Jordan)
- Indian Pharmaceutical Alliance (IPA-India)
- Medicines for Europe (Europe)
- Taiwan Generic Pharmaceutical Association (TGPA-Taiwan)
- In addition, the generic medicines associations of Australia, Mexico, Malaysia, Saudi Arabia, and Brazil are Associate Members